690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study

医学 生物标志物 肿瘤科 内科学 癌症研究 遗传学 生物
作者
Manish R. Patel,Toshihiko Doi,T. Koyama,Gerald S. Falchook,Claire F. Friedman,Sarina A. Piha‐Paul,Martin Gutierrez,Mark M. Awad,Ahmad Mattour,Toshihiko Satoh,Norihiro Okamoto,Jasveer Singh,N. Yoshizuka,Meng Qian,Xiaozhong Qian,Brittany P. Tran,O. Dosunmu,Lu Wang,Melissa L. Johnson
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:34: S481-S482 被引量:3
标识
DOI:10.1016/j.annonc.2023.09.1876
摘要

I-DXd is a novel B7-H3–directed antibody–drug conjugate that leverages the clinically validated deruxtecan (DXd) technology with a plasma-stable linker and potent topoisomerase I inhibitor payload. Here we present a follow-up analysis (7 mo since last report) of an ongoing phase 1/2 trial that includes heavily pretreated patients with castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), squamous non-small cell lung cancer (sqNSCLC), and small cell lung cancer (SCLC). DOR, OS, and B7-H3 correlations with response are reported for the first time for CRPC, ESCC, and sqNSCLC. Efficacy and safety were analyzed in patients treated with I-DXd at 4.8 to 16.0 mg/kg. Response was evaluated in patients with ≥2 postbaseline scans or discontinuation for any reason. Fourteen patients with CRPC lacked measurable target lesions at baseline (BL) and were excluded from ORR analysis. B7-H3 level was evaluated retrospectively as patients were not pre-selected by BL expression. As of 31 Jan 2023, 8 patients remained on treatment. Safety data were consistent with previous reports. I-DXd still demonstrated promising ORR results, including in an updated sample size for sqNSCLC (Table). Even in this heavily pretreated population, I-DXd exhibited durable response and encouraging early OS (Table), although further follow-up is needed. B7-H3 expression was moderate to high in most patients; no correlation was observed between response and B7-H3 level, and an update will be presented at the congress.Table: 690PEfficacyCRPCESCCsqNSCLCSCLCNo. of prior lines, median (range)6 (1 – 11)4 (1 – 7)3 (1 – 12)2 (1 – 9)ORR by RECIST v1.1 (confirmed) n (%)n = 59 15 (25)n = 28 6 (21)n = 13 4 (31)n = 21 11 (52)DOR by RECIST v1.1 Median, mo (95% CI)n = 59 6.4 (2.8 – 10.6)n = 28 3.5 (2.4 – NE)n = 13 4.1 (2.8 – NE)n = 21 5.9 (2.8 – 7.5)PFS by RECIST v1.1 Median, mo (95% CI)n = 73 4.8 (3.9 – 5.9)n = 28 2.8 (1.6 – 4.2)NRn = 21 5.8 (3.9 – 8.1)OS Median, mo (95% CI)n = 73 13.5 (10.3 – 16.6)n = 28 7.0 (4.8 – 12.2)NRn = 21 9.9 (5.8 – NE)DOR, duration of response; NE, not estimable; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors. Open table in a new tab DOR, duration of response; NE, not estimable; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors. I-DXd continues to demonstrate a manageable safety profile and promising antitumor activity with encouraging DOR and OS in these heavily pretreated patients, which warrants further clinical evaluation across multiple indications.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无敌干扰素完成签到,获得积分10
刚刚
TonyXWZhang完成签到,获得积分10
1秒前
在九月完成签到 ,获得积分10
1秒前
fishswim1完成签到,获得积分10
3秒前
刘华珍完成签到,获得积分10
5秒前
5秒前
段辉完成签到,获得积分10
6秒前
Lucas的应助被toppkj采纳,获得10
7秒前
lizhehao完成签到,获得积分10
7秒前
香蕉觅云的应助被紫熊采纳,获得10
7秒前
TY完成签到 ,获得积分10
8秒前
szjqq完成签到,获得积分10
8秒前
rzxhygr完成签到,获得积分10
9秒前
乔凌云完成签到 ,获得积分10
10秒前
天天快乐的应助被学术雷锋采纳,获得10
11秒前
陨落的繁星完成签到,获得积分10
11秒前
务实青筠完成签到 ,获得积分10
12秒前
nusiew完成签到,获得积分10
12秒前
勤奋的毛豆完成签到,获得积分10
12秒前
爱沉淀的太阳花完成签到,获得积分10
13秒前
热心的梦柏完成签到 ,获得积分10
14秒前
织梦完成签到 ,获得积分10
14秒前
tszjw168发布了新的文献求助10
15秒前
szj完成签到,获得积分10
15秒前
星星完成签到 ,获得积分10
16秒前
xixi2517完成签到,获得积分10
16秒前
端庄的猕猴桃完成签到 ,获得积分10
17秒前
bigger.b完成签到,获得积分0
19秒前
rongrong12完成签到,获得积分10
19秒前
seawolf168完成签到,获得积分10
20秒前
海底烤鱼饭完成签到,获得积分10
22秒前
小时完成签到 ,获得积分10
23秒前
苹果思烟完成签到,获得积分10
24秒前
文静的紫萱完成签到,获得积分10
25秒前
苗苗完成签到,获得积分10
26秒前
牙牙完成签到,获得积分10
29秒前
北海完成签到,获得积分10
30秒前
笑点低的凉面完成签到,获得积分10
34秒前
zzzzlololo完成签到,获得积分10
36秒前
系统昵称完成签到,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719706
捐赠科研通 7748769
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428